A biopharma CDMO contract is a vital risk-control mechanism across CMC, quality, and regulatory operations, not a mere procurement formality. Standard agreements frequently appear complete until a failed batch, delayed clinical supply, or stalled data transfer exposes unassigned liability.
Drawing on our integrated CMC, quality, regulatory, and external-manufacturing oversight, here are eight practical contracting checks spanning first-in-human supply through commercial production, starting with the contract-document stack.
1. Align the Three-Document Hierarchy and Establish an Order of Precedence
CDMO contracts fail when obligations conflict across separate documents. A reliable governance structure requires three aligned agreements: an MSA for commercial risk and liability, an SOW for scope, pricing, and milestones, and a Quality Agreement for GMP responsibilities.
Never allow a generic MSA clause to override technical commitments. Enforce an explicit, subject-matter order of precedence where the Quality Agreement controls cGMP, deviations, change control, and batch release, while the SOW controls project-specific deliverables.
Before execution, verify responsibilities through a compact RACI check:
| RACI Check | Responsibility |
|---|---|
| Batch records | CDMO drafts; sponsor approves. |
| OOS investigations | CDMO leads; sponsor concurs. |
| Batch release | CDMO issues technical release; sponsor retains regulatory release. |
| Agency inspections | CDMO notifies sponsor within 24 to 48 hours. |
We integrate this framework into our CDMO selection and management support to prevent operational disputes.
2. Lock Down SOW Assumptions, Acceptance Criteria, and Change Controls
A common pitfall in CDMO contracting is signing a Statement of Work that outlines broad activities but omits operational assumptions, deliverables, decision deadlines, and objective acceptance criteria. This ambiguity sparks disputes over whether work is complete, late, or billable.
An enforceable CDMO contract locks down operational details upfront:
- Batch size and campaign yield assumptions
- Analytical methods and stability deliverables
- Milestone schedules and sponsor review windows
- Release specifications and documentation formats
Mandate that work outside scope requires a written, sponsor-approved change order before invoices generate or timelines shift. In first-in-human programs, establish clear batch sizes, rapid stability milestones, and formulation-pivot gates for proceeding to GMP manufacture. Phase-appropriate CMC planning must directly shape the SOW, rather than being retrofitted after booking a manufacturing slot.
3. Define Failed Batches and Establish Tiered Liability Buckets
A failed batch can derail clinical milestones overnight. If your CDMO contract offers only a processing fee refund, you remain fully exposed to the cost of wasted API and forfeited manufacturing slots.
Define what constitutes a failed batch across both the SOW and Quality Agreement, including confirmed out-of-specification results, critical cGMP deviations, or missed release specifications. Divide responsibility into three fault buckets:
| Fault Bucket | Responsibility |
|---|---|
| CDMO fault | Operational negligence or non-compliance triggers a CDMO-funded re-run, priority re-slotting, and agreed material reimbursement. |
| Sponsor material defect | The sponsor absorbs costs if customer-supplied starting materials fail verified specifications. |
| Development uncertainty | Early-phase scale-up and process risks follow pre-agreed, shared-risk terms. |
Require defined timelines for batch record and CoA reviews, paired with a formal technical dispute escalation process to resolve root causes before disputes delay progress.
4. Right-Size Liability Caps and Carve-Outs for True Material Risk
Standard CDMO agreements routinely cap aggregate liability at fees paid under a single Statement of Work, alongside broad consequential-damages exclusions. You must test whether that cap realistically covers the full financial exposure of lost sponsor-supplied API, batch re-manufacture, and time-sensitive clinical supply interruptions.
Collaborate with legal counsel to negotiate explicit, uncapped or super-capped carve-outs for:
- Gross negligence and willful misconduct
- Confidentiality breaches and data loss
- Regulatory debarment and compliance failures
- Third-party intellectual property infringement
A well-structured CDMO contract must also distinguish first-in-human shared technical uncertainty from preventable execution or GMP failures. Never apply a blanket liability remedy to both inherent scientific development risk and avoidable vendor error.
Always engage qualified life-sciences counsel to evaluate governing-law, liability, and remedy provisions tailored to your program.
5. Secure Tech Transfer Rights Across Foreground, Background, and Platform IP
Assuming drug product ownership automatically grants the rights needed to replicate a process elsewhere is a common, costly pitfall. Without precise partitioning in your CDMO contract, tech transfers stall over proprietary vendor platforms, leaving sponsors dependent on a single manufacturer.
Partition intellectual property across three distinct categories:
| IP Category | Contract Requirement |
|---|---|
| Sponsor Background IP | Pre-existing proprietary rights and patents brought to the project. |
| Product-Specific Foreground IP | New improvements generated during development, which the sponsor must own outright. |
| CDMO Platform IP | Pre-existing vendor processes, requiring a perpetual, royalty-free, transferable license to manufacture or transfer the product. |
Tie IP provisions directly to tangible deliverables: analytical methods, batch records, validation packages, process parameters, and raw data. Review these rights alongside formal exit-assistance terms rather than treating IP as an isolated legal review.
6. Align Slot Reservations, Forecasts, and Cancellation Terms to Program Maturity
A frequent pitfall in clinical development is copying commercial terms into an early agreement without aligning them to program maturity and demand uncertainty. Committing to rigid reservation deposits, minimum order quantities, take-or-pay obligations, or binding forecasts exposes your budget to steep penalties if clinical timelines shift.
For a first-in-human program, structure your CDMO contract with modest slot-reservation deposits, short acceptance windows, formulation-pivot flexibility, and a transparent cancellation schedule. As assets advance toward late-stage pharmaceutical development, commercial terms should introduce rolling forecasts, defined binding windows, flexibility bands, step-up pricing, and fee mitigation when the CDMO reallocates suite capacity.
Require each SOW to state explicitly when manufacturing capacity becomes firm, what occurs if the sponsor misses a decision date, and what fees may be charged.
7. Standardize SOW Pricing Matrices to Prevent Scope Creep
Surprise invoices under a CDMO contract rarely stem from base manufacturing fees. Instead, unbudgeted costs accumulate across routine operational tasks:
- Analytical-method transfer and refinement
- Stability sample pulls and storage
- Deviation investigations and batch-record changes
- Tech-transfer support and additional project management
To prevent budget creep, embed an itemized pricing matrix into your SOW. Specify fixed fees or unit rates, baseline assumptions, hourly caps, and not-to-exceed thresholds for common change categories. Enforce an explicit governance standard: no out-of-scope work, fee, or timeline extension begins without prior documented sponsor approval.
Finally, link technical change control under the Quality Agreement directly to commercial change orders under the SOW. This alignment makes sure operational modifications cannot trigger unreviewed financial obligations. Applying proactive governance to your CDMO relationship protects capital throughout fast-moving development campaigns.
8. Mandate Clear Exit Terms and Technology Transfer Support
Transitioning to a new manufacturing partner without defined exit terms introduces requalification bottlenecks, regulatory coordination delays, and slow access to records. A resilient CDMO contract defines explicit exit triggers, including recurring quality failures, missed milestones, lost facility capacity, or dual-sourcing requirements.
To preserve supply continuity, mandate transfer deliverables in your agreement:
- Analytical methods, raw data, and validation protocols
- Master batch records, executed lots, and deviation or OOS histories
- Stability data and related regulatory correspondence
Specify binding service levels, including firm delivery deadlines, pre-agreed technical support rates, not-to-exceed transfer fees, and escalation paths for unavailable personnel. Secure an escrow mechanism or irrevocable license for CDMO-owned platform elements required to keep your product transferable.
Contact Our Team to Review Your CDMO Contract
Frequently Asked Questions
What is the difference between an MSA, SOW, and Quality Agreement?
A Master Services Agreement (MSA) governs overarching legal and commercial terms, while a Statement of Work (SOW) defines project milestones, pricing, and operational deliverables. A Quality Agreement establishes cGMP roles and regulatory accountability. Your CDMO contract must include explicit precedence language so quality terms always control GMP compliance while the SOW dictates specific scope.
What should a first-in-human CDMO contract include?
A first-in-human CDMO contract requires flexible slot reservations, clear clinical-batch acceptance criteria, early stability milestones, and transparent change-order terms. The agreement should account for technical development uncertainty during initial scale-up without excusing preventable operational errors or GMP execution failures.
Who is responsible if a CDMO batch fails?
Responsibility depends on investigation findings and defined contract fault categories. When a failure stems from vendor negligence or process deviation, the CDMO should provide a funded re-run and API reimbursement up to negotiated liability caps. If failures stem from sponsor-supplied materials or baseline development uncertainty, costs are allocated accordingly.
Can a sponsor switch CDMOs after clinical manufacturing begins?
Yes, but transferring production requires complete batch records, validated analytical methods, regulatory updates, and potential facility requalification. To avoid costly delays, secure tech-transfer-out support, defined consulting rates, and platform licenses in your initial CDMO contract before an exit becomes urgent.
For expert guidance on CDMO selection, contract-risk review, and external manufacturing oversight, contact our team today.
